Trevi Therapeutics Execs to Present at Three September Conferences
Event summary
- Trevi Therapeutics executives will participate in three healthcare conferences in September 2026.
- CEO Jennifer Good and CFO David Hastings will present at the Cantor Global Healthcare Conference on September 10.
- CEO Jennifer Good and CCO Farrell Simon will present at the H.C. Wainwright Conference on September 14.
- CEO Jennifer Good and CDO James Cassella will present at the Morgan Stanley Conference on September 15.
- CDO James Cassella will participate in two panel discussions at the IPF Summit on October 1.
The big picture
Trevi Therapeutics is actively engaging with investors and industry experts through multiple conferences, highlighting its focus on advancing Haduvio for chronic cough indications. The company is operating in a niche market with high unmet medical needs, particularly in IPF and RCC patients. These presentations provide a platform to discuss clinical data, regulatory pathways, and market potential, which are critical for securing partnerships and funding.
What we're watching
- Clinical Progress
- How Trevi Therapeutics will update investors on Haduvio's clinical trial progress and regulatory strategy.
- Market Positioning
- Whether Trevi can differentiate Haduvio in the competitive landscape of chronic cough treatments.
- Investor Sentiment
- The impact of these presentations on Trevi's stock performance and investor confidence.